A case-control pharmacovigilance study of TNF-alpha inhibitors and interleukin inhibitors on tuberculosis, Candida, lymphoma and suicidality using the FAERS database (2014-2020)

Domenico Arcuri; Mohammed Kaouache; François Lagacé; Denis Sasseville; Ivan Litvinov

doi:10.1016/j.jaad.2023.05.041

A case-control pharmacovigilance study of TNF-alpha inhibitors and interleukin inhibitors on tuberculosis, Candida, lymphoma and suicidality using the FAERS database (2014-2020)

J Am Acad Dermatol. 2023 Sep;89(3):619-621. doi: 10.1016/j.jaad.2023.05.041. Epub 2023 May 26.

Authors

Domenico Arcuri¹, Mohammed Kaouache², François Lagacé², Denis Sasseville², Ivan Litvinov²

Affiliations

¹ McGill University - Faculty of Medicine and Health Sciences, Montreal, Quebec, Canada. Electronic address: Domenico.arcuri@mail.mcgill.ca.
² McGill University - Faculty of Medicine and Health Sciences, Montreal, Quebec, Canada.

PMID: 37245836
DOI: 10.1016/j.jaad.2023.05.041

No abstract available

Keywords: Bayesian analysis; Candida; EBGM; FAERS; TNF-Alpha; TNF-Alpha Inhibitor; adverse event; biologics; drug reaction; drugs; general dermatology; interleukin; interleukin inhibitor; lymphoma; medical dermatology; medications; pharmacovigilance; psoriasis; psoriatic arthritis; reporting odds ratio; suicide; tuberculosis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adverse Drug Reaction Reporting Systems
Candida
Case-Control Studies
Humans
Interleukin Inhibitors
Lymphoma* / drug therapy
Lymphoma* / epidemiology
Pharmacovigilance
Suicide*
Tuberculosis*
Tumor Necrosis Factor Inhibitors
Tumor Necrosis Factor-alpha
United States
United States Food and Drug Administration

Substances

Tumor Necrosis Factor-alpha
Interleukin Inhibitors
Tumor Necrosis Factor Inhibitors